PL2651436T3 - Kompozycja antygenów mykobakteryjnych - Google Patents

Kompozycja antygenów mykobakteryjnych

Info

Publication number: PL2651436T3
Authority: PL; Poland
Prior art keywords: antigenic composition; mycobacterium; mycobacterium antigenic; composition; antigenic
Prior art date: 2010-12-14

Application number

PL11794778.8T

Other languages

English (en)

Inventor

Stephane Andre Georges Godart

Amina Laanan

Dominique Ingrid Lemoine

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-14

Filing date

2011-12-14

Publication date

2016-10-31

2011-12-14 Application filed filed Critical

2016-10-31 Publication of PL2651436T3 publication Critical patent/PL2651436T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Pulmonology (AREA)
Mycology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Virology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

PL11794778.8T 2010-12-14 2011-12-14 Kompozycja antygenów mykobakteryjnych PL2651436T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US42272310P	2010-12-14	2010-12-14

Publications (1)

Publication Number	Publication Date
PL2651436T3 true PL2651436T3 (pl)	2016-10-31

Family

ID=45346501

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL11799673T PL2651437T3 (pl)	2010-12-14	2011-12-14	Kompozycja antygenów mykobakteryjnych
PL15201196T PL3023106T3 (pl)	2010-12-14	2011-12-14	Kompozycja antygenów mykobakteryjnych
PL11794778.8T PL2651436T3 (pl)	2010-12-14	2011-12-14	Kompozycja antygenów mykobakteryjnych

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL11799673T PL2651437T3 (pl)	2010-12-14	2011-12-14	Kompozycja antygenów mykobakteryjnych
PL15201196T PL3023106T3 (pl)	2010-12-14	2011-12-14	Kompozycja antygenów mykobakteryjnych

Country Status (33)

Country	Link
US (5)	US9730992B2 (pl)
EP (4)	EP2651436B1 (pl)
JP (2)	JP5951633B2 (pl)
KR (3)	KR20140029376A (pl)
CN (4)	CN103249431B (pl)
AR (1)	AR084285A1 (pl)
AU (2)	AU2011343367B2 (pl)
BR (2)	BR112013014599A2 (pl)
CA (2)	CA2819297A1 (pl)
CO (2)	CO6751287A2 (pl)
CY (1)	CY1122187T1 (pl)
DK (3)	DK3023106T3 (pl)
EA (2)	EA027504B1 (pl)
ES (3)	ES2748651T3 (pl)
HR (3)	HRP20160606T1 (pl)
HU (3)	HUE028452T2 (pl)
IL (2)	IL226450A0 (pl)
LT (1)	LT3023106T (pl)
ME (1)	ME02380B (pl)
MX (2)	MX344706B (pl)
MY (1)	MY161412A (pl)
PH (2)	PH12013501203A1 (pl)
PL (3)	PL2651437T3 (pl)
PT (2)	PT2651436E (pl)
RS (1)	RS54687B1 (pl)
SG (2)	SG190937A1 (pl)
SI (3)	SI2651437T1 (pl)
SM (1)	SMT201600118B (pl)
TW (1)	TW201305192A (pl)
UA (2)	UA110118C2 (pl)
UY (1)	UY33802A (pl)
WO (2)	WO2012080369A1 (pl)
ZA (2)	ZA201304014B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2457926T3 (pl)	2005-04-29	2015-03-31	Glaxosmithkline Biologicals Sa	Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
HUE028452T2 (en) *	2010-12-14	2016-12-28	Glaxosmithkline Biologicals Sa	Mycobacterium antigenic preparations
PL2661253T3 (pl)	2011-01-04	2017-08-31	Archivel Farma, Sl	Preparat liposomowy odpowiedni do leczenia lub zapobiegania gruźlicy
ES2670493T3 (es)	2012-01-12	2018-05-30	Archivel Farma, S.L.	Vacuna de MTB-C contra respuestas alérgicas
US9993427B2 (en)	2013-03-14	2018-06-12	Biorest Ltd.	Liposome formulation and manufacture
GB201405921D0 (en)	2014-04-02	2014-05-14	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
US11400115B2 (en)	2014-04-23	2022-08-02	Juno Therapeutics, Inc.	Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
GB201513176D0 (en) *	2015-07-27	2015-09-09	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
GB201522068D0 (en)	2015-12-15	2016-01-27	Glaxosmithkline Biolog Sa	Dried composition
CN110035770B (zh)	2016-12-07	2023-06-16	葛兰素史密丝克莱恩生物有限公司	新方法
GB201621686D0 (en)	2016-12-20	2017-02-01	Glaxosmithkline Biologicals Sa	Novel methods for inducing an immune response
GB201707700D0 (en)	2017-05-12	2017-06-28	Glaxosmithkline Biologicals Sa	Dried composition
FR3066920A1 (fr)	2017-05-30	2018-12-07	Glaxosmithkline Biologicals S.A.	Nouveaux procedes de fabrication d'un adjuvant
WO2019106192A1 (en)	2017-12-01	2019-06-06	Glaxosmithkline Biologicals Sa	Saponin purification
RU2728976C2 (ru) *	2018-03-22	2020-08-03	Зули Холдингз, Лтд.	Липосомный состав и его получение
US20210292395A1 (en)	2018-07-31	2021-09-23	Glaxosmithkline Biologicals Sa	Antigen purification method
WO2020109365A1 (en)	2018-11-29	2020-06-04	Glaxosmithkline Biologicals Sa	Methods for manufacturing an adjuvant
CA3142300C (en)	2019-06-05	2025-02-04	Glaxosmithkline Biologicals Sa	SAPONIN PURIFICATION
EP3777884A1 (en)	2019-08-15	2021-02-17	GlaxoSmithKline Biologicals S.A.	Immunogenic composition
CN114466659A (zh)	2019-09-09	2022-05-10	葛兰素史克生物有限公司	免疫治疗组合物
JP2023503086A (ja)	2019-11-22	2023-01-26	グラクソスミスクラインバイオロジカルズソシエテアノニム	細菌サッカリド複合糖質ワクチンの用法及び用量
MX2022013855A (es)	2020-05-05	2022-11-30	Glaxosmithkline Biologicals Sa	Dispositivos de mezcla de microfluidos y metodos de uso.
US20230234992A1 (en)	2020-06-05	2023-07-27	Glaxosmithkline Biologicals Sa	Modified betacoronavirus spike proteins
CA3203278A1 (en)	2020-12-09	2022-06-16	Glaxosmithkline Biologicals Sa	Saponins
CN114034860A (zh) *	2021-11-01	2022-02-11	宁夏大学	一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
JP2025525334A (ja)	2022-06-15	2025-08-05	グラクソスミスクラインバイオロジカルズソシエテアノニム	サポニンの酵素的修飾
CN116120411B (zh) *	2022-12-07	2024-04-12	中国疾病预防控制中心传染病预防控制所	结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
CA1331443C (en)	1987-05-29	1994-08-16	Charlotte A. Kensil	Saponin adjuvant
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
DE69015222T2 (de)	1989-02-04	1995-05-04	Akzo Nv	Tocole als Impfstoffadjuvans.
ES2162139T5 (es)	1993-03-23	2008-05-16	Smithkline Beecham Biologicals S.A.	Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
EP0772619B2 (en)	1994-07-15	2010-12-08	The University of Iowa Research Foundation	Immunomodulatory oligonucleotides
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DK1398379T3 (da)	1995-09-01	2007-01-08	Corixa Corp	Forbindelser og fremgangsmåder til immunterapi og diagnose af tuberkulose
ES2378051T3 (es)	1995-09-01	2012-04-04	Corixa Corporation	Compuestos y métodos para el diagnóstico de la tubercolosis.
US5666153A (en)	1995-10-03	1997-09-09	Virtual Shopping, Inc.	Retractable teleconferencing apparatus
GB9619613D0 (en)	1996-09-19	1996-10-30	Breed Automotive Tech	An inflatable restraint for a vehicle
EP0859366A1 (en)	1997-02-12	1998-08-19	STMicroelectronics S.r.l.	Associative memory device with optimized occupation, particularly for the recognition of words
JP4598201B2 (ja) *	1997-04-08	2010-12-15	メルク・シャープ・エンド・ドーム・コーポレイション	安定化ヒトパピローマウイルス製剤
US6303347B1 (en)	1997-05-08	2001-10-16	Corixa Corporation	Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en)	1997-05-08	2000-09-05	Ribi Immunochem Research, Inc.	Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en)	1997-05-08	2004-07-20	Corixa Corporation	Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en)	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
DE19803453A1 (de) *	1998-01-30	1999-08-12	Boehringer Ingelheim Int	Vakzine
WO1999051748A2 (en)	1998-04-07	1999-10-14	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO1999052549A1 (en) *	1998-04-09	1999-10-21	Smithkline Beecham Biologicals S.A.	Adjuvant compositions
US6551600B2 (en)	1999-02-01	2003-04-22	Eisai Co., Ltd.	Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en)	1999-02-01	2004-01-08	Hawkins Lynn D.	Immunomodulatory compounds and method of use thereof
JP2003510370A (ja) *	1999-10-07	2003-03-18	コリクサコーポレイション	Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓの融合タンパク質
AU6867801A (en) *	2000-06-20	2002-01-02	Corixa Corp	Fusion proteins of mycobacterium tuberculosis
CZ20024224A3 (cs)	2000-06-29	2003-05-14	Glaxosmithkline Biologicals S. A.	Farmaceutický prostředek
WO2003070187A2 (en)	2002-02-15	2003-08-28	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en)	2004-05-21	2004-06-23	Glaxosmithkline Biolog Sa	Vaccines
PL2457926T3 (pl) *	2005-04-29	2015-03-31	Glaxosmithkline Biologicals Sa	Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
EP2368568A1 (en) *	2006-11-01	2011-09-28	Immport Therapeutics, INC.	Compositions and methods for immunodominant antigens
US20090035360A1 (en)	2007-05-24	2009-02-05	Dominique Ingrid Lemoine	Lyophilised antigen composition
TWI661833B (zh)	2007-11-30	2019-06-11	百慕達商艾伯維生物技術有限責任公司	蛋白質調配物及製造其之方法
KR100955470B1 (ko) *	2008-01-09	2010-04-30	대한민국(관리부서 질병관리본부장)	탄저 방어 항원의 제조 방법
WO2009111874A1 (en)	2008-03-11	2009-09-17	The Royal Institution For The Advancement Of Learning/ Mcgiil University	Low-temperature wafer level processing for mems devices
GB0910046D0 (en) *	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions
GB0910045D0 (en) *	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions
GB201008512D0 (en)	2010-05-21	2010-07-07	Health Prot Agency	Mycobacterial antigen composition
IT1400834B1 (it)	2010-07-07	2013-07-02	Aero Sekur S P A	Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
HUE028452T2 (en)	2010-12-14	2016-12-28	Glaxosmithkline Biologicals Sa	Mycobacterium antigenic preparations
GB201400819D0 (en)	2014-01-17	2014-03-05	Sec Dep For Health The	Mycobacterial antigen composition

2011
- 2011-12-14 HU HUE11794778A patent/HUE028452T2/en unknown
- 2011-12-14 ME MEP-2016-60A patent/ME02380B/me unknown
- 2011-12-14 ES ES15201196T patent/ES2748651T3/es active Active
- 2011-12-14 SI SI201130787A patent/SI2651437T1/sl unknown
- 2011-12-14 SG SG2013041918A patent/SG190937A1/en unknown
- 2011-12-14 JP JP2013543775A patent/JP5951633B2/ja active Active
- 2011-12-14 JP JP2013543776A patent/JP5951634B2/ja active Active
- 2011-12-14 BR BR112013014599A patent/BR112013014599A2/pt not_active Application Discontinuation
- 2011-12-14 DK DK15201196.1T patent/DK3023106T3/da active
- 2011-12-14 PT PT117947788T patent/PT2651436E/pt unknown
- 2011-12-14 HR HRP20160606TT patent/HRP20160606T1/hr unknown
- 2011-12-14 CN CN201180060222.7A patent/CN103249431B/zh not_active Expired - Fee Related
- 2011-12-14 US US13/993,386 patent/US9730992B2/en active Active
- 2011-12-14 HU HUE11799673A patent/HUE027932T2/en unknown
- 2011-12-14 AR ARP110104678A patent/AR084285A1/es unknown
- 2011-12-14 DK DK11799673.6T patent/DK2651437T3/en active
- 2011-12-14 EP EP11794778.8A patent/EP2651436B1/en active Active
- 2011-12-14 WO PCT/EP2011/072816 patent/WO2012080369A1/en not_active Ceased
- 2011-12-14 PL PL11799673T patent/PL2651437T3/pl unknown
- 2011-12-14 DK DK11794778.8T patent/DK2651436T3/da active
- 2011-12-14 PT PT152011961T patent/PT3023106T/pt unknown
- 2011-12-14 RS RS20160225A patent/RS54687B1/sr unknown
- 2011-12-14 CN CN201180060489.6A patent/CN103260642B/zh not_active Expired - Fee Related
- 2011-12-14 PH PH1/2013/501203A patent/PH12013501203A1/en unknown
- 2011-12-14 AU AU2011343367A patent/AU2011343367B2/en not_active Ceased
- 2011-12-14 MX MX2013006818A patent/MX344706B/es active IP Right Grant
- 2011-12-14 TW TW100146325A patent/TW201305192A/zh unknown
- 2011-12-14 UA UAA201306355A patent/UA110118C2/uk unknown
- 2011-12-14 BR BR112013014598A patent/BR112013014598A2/pt not_active Application Discontinuation
- 2011-12-14 US US13/993,736 patent/US9352030B2/en active Active
- 2011-12-14 MX MX2013006819A patent/MX344280B/es active IP Right Grant
- 2011-12-14 ES ES11794778.8T patent/ES2574403T3/es active Active
- 2011-12-14 PL PL15201196T patent/PL3023106T3/pl unknown
- 2011-12-14 PL PL11794778.8T patent/PL2651436T3/pl unknown
- 2011-12-14 EA EA201390630A patent/EA027504B1/ru not_active IP Right Cessation
- 2011-12-14 EP EP19188906.2A patent/EP3593813A1/en not_active Withdrawn
- 2011-12-14 CN CN201710066847.3A patent/CN106822883A/zh active Pending
- 2011-12-14 EP EP11799673.6A patent/EP2651437B1/en active Active
- 2011-12-14 UA UAA201306356A patent/UA110806C2/uk unknown
- 2011-12-14 WO PCT/EP2011/072817 patent/WO2012080370A1/en not_active Ceased
- 2011-12-14 SI SI201131805T patent/SI3023106T1/sl unknown
- 2011-12-14 HU HUE15201196A patent/HUE045766T2/hu unknown
- 2011-12-14 PH PH1/2013/501204A patent/PH12013501204A1/en unknown
- 2011-12-14 KR KR1020137018059A patent/KR20140029376A/ko not_active Withdrawn
- 2011-12-14 ES ES11799673.6T patent/ES2567190T3/es active Active
- 2011-12-14 CN CN201610883668.4A patent/CN106822882A/zh active Pending
- 2011-12-14 KR KR1020197004934A patent/KR20190022897A/ko not_active Ceased
- 2011-12-14 CA CA2819297A patent/CA2819297A1/en not_active Abandoned
- 2011-12-14 AU AU2011343368A patent/AU2011343368C1/en not_active Ceased
- 2011-12-14 SI SI201130859A patent/SI2651436T1/sl unknown
- 2011-12-14 CA CA2819298A patent/CA2819298A1/en not_active Abandoned
- 2011-12-14 HR HRP20160362TT patent/HRP20160362T1/hr unknown
- 2011-12-14 LT LT15201196T patent/LT3023106T/lt unknown
- 2011-12-14 KR KR1020137018060A patent/KR101951894B1/ko not_active Expired - Fee Related
- 2011-12-14 EA EA201390631A patent/EA027920B1/ru not_active IP Right Cessation
- 2011-12-14 EP EP15201196.1A patent/EP3023106B1/en active Active
- 2011-12-14 UY UY0001033802A patent/UY33802A/es not_active Application Discontinuation
- 2011-12-14 MY MYPI2013700989A patent/MY161412A/en unknown
- 2011-12-14 SG SG2013041793A patent/SG190731A1/en unknown
2013
- 2013-05-20 IL IL226450A patent/IL226450A0/en unknown
- 2013-05-20 IL IL226448A patent/IL226448A/en active IP Right Grant
- 2013-05-31 ZA ZA2013/04014A patent/ZA201304014B/en unknown
- 2013-05-31 ZA ZA2013/04015A patent/ZA201304015B/en unknown
- 2013-06-19 CO CO13146289A patent/CO6751287A2/es unknown
- 2013-06-19 CO CO13146307A patent/CO6751288A2/es unknown
2016
- 2016-04-18 US US15/131,422 patent/US20160220656A1/en not_active Abandoned
- 2016-04-22 SM SM201600118T patent/SMT201600118B/it unknown
2017
- 2017-07-06 US US15/643,084 patent/US10441648B2/en active Active
2019
- 2019-02-08 US US16/270,887 patent/US20190183998A1/en not_active Abandoned
- 2019-10-11 HR HRP20191843TT patent/HRP20191843T1/hr unknown
- 2019-10-18 CY CY20191101093T patent/CY1122187T1/el unknown

Also Published As

Publication number	Publication date
PT3023106T (pt)	2019-11-04
EP3023106B1 (en)	2019-07-31
HRP20191843T1 (hr)	2019-12-27
CO6751287A2 (es)	2013-09-16
HUE027932T2 (en)	2016-11-28
US20180071378A1 (en)	2018-03-15
DK3023106T3 (da)	2019-09-30
CY1122187T1 (el)	2020-11-25
US9730992B2 (en)	2017-08-15
ES2567190T3 (es)	2016-04-20
CN103249431B (zh)	2016-11-02
PL2651437T3 (pl)	2016-07-29
ZA201304014B (en)	2017-04-26
UY33802A (es)	2012-07-31
HRP20160606T1 (hr)	2016-07-01
SI3023106T1 (sl)	2019-11-29
UA110806C2 (uk)	2016-02-25
BR112013014599A2 (pt)	2016-09-27
KR20140029376A (ko)	2014-03-10
JP5951633B2 (ja)	2016-07-13
US20190183998A1 (en)	2019-06-20
ES2574403T3 (es)	2016-06-17
HUE028452T2 (en)	2016-12-28
AU2011343367A1 (en)	2013-07-11
AU2011343368C1 (en)	2015-12-24
EA027504B1 (ru)	2017-08-31
US20130280289A1 (en)	2013-10-24
AU2011343367B2 (en)	2015-05-21
CO6751288A2 (es)	2013-09-16
MX344706B (es)	2017-01-03
EP3593813A1 (en)	2020-01-15
MY161412A (en)	2017-04-14
JP2013545783A (ja)	2013-12-26
EP2651437A1 (en)	2013-10-23
EP2651436A1 (en)	2013-10-23
KR101951894B1 (ko)	2019-02-26
CN103260642A (zh)	2013-08-21
UA110118C2 (uk)	2015-11-25
PT2651436E (pt)	2016-06-08
AU2011343368B2 (en)	2015-08-20
WO2012080370A1 (en)	2012-06-21
JP5951634B2 (ja)	2016-07-13
LT3023106T (lt)	2019-10-25
KR20190022897A (ko)	2019-03-06
EA201390630A1 (ru)	2013-12-30
CN103249431A (zh)	2013-08-14
BR112013014598A2 (pt)	2017-09-19
JP2014505036A (ja)	2014-02-27
DK2651436T3 (da)	2016-06-20
CA2819298A1 (en)	2012-06-21
SG190937A1 (en)	2013-07-31
CA2819297A1 (en)	2012-06-21
EP2651437B1 (en)	2016-02-10
EP2651436B1 (en)	2016-03-30
HRP20160362T1 (hr)	2016-05-06
HUE045766T2 (hu)	2020-01-28
US20130287809A1 (en)	2013-10-31
CN106822883A (zh)	2017-06-13
ME02380B (me)	2016-06-20
US10441648B2 (en)	2019-10-15
US9352030B2 (en)	2016-05-31
ES2748651T3 (es)	2020-03-17
PH12013501203A1 (en)	2013-07-29
ZA201304015B (en)	2018-12-19
PH12013501204A1 (en)	2013-07-29
EA201390631A1 (ru)	2014-11-28
IL226450A0 (en)	2013-07-31
PL3023106T3 (pl)	2019-12-31
IL226448A0 (en)	2013-07-31
MX2013006818A (es)	2013-08-26
MX344280B (es)	2016-12-09
SMT201600118B (it)	2016-07-01
US20160220656A1 (en)	2016-08-04
AU2011343368A1 (en)	2013-07-11
SG190731A1 (en)	2013-07-31
IL226448A (en)	2017-09-28
KR20130124525A (ko)	2013-11-14
EP3023106A1 (en)	2016-05-25
WO2012080369A1 (en)	2012-06-21
AR084285A1 (es)	2013-05-08
CN106822882A (zh)	2017-06-13
SI2651437T1 (sl)	2016-05-31
TW201305192A (zh)	2013-02-01
RS54687B1 (sr)	2016-08-31
SI2651436T1 (sl)	2016-07-29
DK2651437T3 (en)	2016-05-02
MX2013006819A (es)	2013-08-26
EA027920B1 (ru)	2017-09-29
CN103260642B (zh)	2018-03-16

Publication	Publication Date	Title
ZA201304015B (en)	2018-12-19	Mycobacterium antigenic composition
GB201003924D0 (en)	2010-04-21	Immunogenic composition
GB201002983D0 (en)	2010-04-07	Nutritinal composition
GB201006200D0 (en)	2010-06-02	Composition
GB201021186D0 (en)	2011-01-26	Composition
GB201015132D0 (en)	2010-10-27	Vaccine composition
ZA201208093B (en)	2013-06-26	Mycobacterial antigen composition
GB201021269D0 (en)	2011-01-26	Composition
GB201019988D0 (en)	2011-01-05	Composition
GB201005927D0 (en)	2010-05-26	Improved composition
GB201007531D0 (en)	2010-06-23	Composition
GB201006214D0 (en)	2010-06-02	Composition
GB201004717D0 (en)	2010-05-05	Composition
GB201014967D0 (en)	2010-10-20	Composition
GB201010657D0 (en)	2010-08-11	Composition
GB201018130D0 (en)	2010-12-08	Composition
GB201006175D0 (en)	2010-06-02	Composition
GB201006182D0 (en)	2010-06-02	Composition
GB201006012D0 (en)	2010-05-26	Composition
GB201002356D0 (en)	2010-03-31	Composition
HK1190619A (en)	2014-07-11	Mycobacterium antigenic composition
HK1190618A (en)	2014-07-11	Mycobacterium antigenic composition
GB201003918D0 (en)	2010-04-21	Immunogenic composition
GB201006369D0 (en)	2010-06-02	Polysiloxane composition
GB201003347D0 (en)	2010-04-14	Tppical composition